CIRCE Scientific has recently carried out a capital increase in which it has raised 1.7 million euros (>1.8 million USD). The capital increase has been attended by current shareholders and has led to the entry into the company of new national and international shareholders.
With these funds raised, CIRCE will continue the development of its go to market strategy, cover its short and long-term financing needs and achieve its growth forecasts.
First, it will focus on its industrial growth and start manufacturing commercial batches of its first ingredient, PTEROVITA, for its launch in the US.
It will as well accelerate the registration and entry into new markets after signing new distribution contracts with strategic partners.
It will also launch new clinical studies with the ingredients developed in different health areas, scale up the production of its Sitosterol Cocrystal, and reinforce the R&D of more ingredients in its pipeline.
After years of research on the development of improved nutraceutical ingredients, the company is stepping into a new phase with the launch of PTEROVITA in Q1 2023.
CIRCE Scientific is an emerging and innovative nutraceutical company focused on using cocrystal technology to produce nutraceutical ingredients with enhanced properties.
If you want to learn more about our investment opportunities, contact us here.